Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
This research will test whether a standard version or very low-carbohydrate version of the Diabetes Prevention Program better improves outcomes like blood glucose control and body weight for patients with prediabetes.
Participants will have screening (includes blood draw) and baseline testing with a continuous glucose monitor. Once these enrollment steps are completed and the participants will be randomized to one of two groups: standard National Diabetes Prevention Program (NDPP) or a very low-carbohydrate version.
In addition to the diet (12 months) participants will be asked to participate in hour-long weekly group classes over zoom. After four months in the program, classes will occur about every month to help participants maintain the new diet. There will also be check-ins and follow-up visits through out the study.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
history of type 1 diabetes or type 2 diabetes
use of anti-obesity medications or participation in another weight loss program or intervention
use of glucose lowering medications other than metformin
pregnant or planning to become pregnant during the intervention period
breastfeeding
use of oral corticosteroids
previous bariatric surgery or planning to have bariatric surgery during the study period
blood disorders that influence HbA1c, including frequent blood transfusions, phlebotomy, anemia, hemoglobinopathy, polycythemia
any condition for which the study team deems participation to be unsafe or inappropriate
inability to read, write, or speak English
inability to provide informed consent
adherence to a vegan or vegetarian diet
adherence to a very low-carbohydrate (keto) diet
difficulty chewing or swallowing
no influence over what foods are purchased, prepared, and/or served
above weight limit for DEXA (500 pounds)
untreated eating disorder or mental health conditions, such as depression with suicidal ideation, bipolar or schizophrenia with psychosis
use of warfarin
chronic kidney disease, stage 4 or higher
use of loop diuretics: 20mg or higher of furosemide or equivalent (Lasix (furosemide), Bumex (bumetanide), Ederin or Sodium Edecrin (ethacrynic acid), Demadex or Soaanz (torsemide))
any concerning values in baseline labs (participants will be referred to Primary Care Physician and will be allowed to return for later enrollment if labs are no longer concerning)
Primary purpose
Allocation
Interventional model
Masking
304 participants in 2 patient groups
Loading...
Central trial contact
Laura Saslow, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal